title: Restoration of the acute phase response after infection in cyclophosphamide-treated mice by granulocyte colony-stimulating factor.
abstract: The therapeutic effect of granulocyte colony-stimulating factor (G-CSF) against intramuscular infection with Pseudomonas aeruginosa in cyclophosphamide (CY)-treated mice was analyzed by measuring plasma levels of amyloid P-component (APC) and proinflammatory cytokine levels. CY (100 mg/kg) treatment of mice significantly suppressed plasma concentrations of APC and tumor-necrosis factor-alpha (TNF-alpha) following infection with P. aeruginosa, in associated with enhanced susceptibility of the treated mice to this bacterium. A 4-day treatment of CY-treated mice with recombinant human G-CSF (rhG-CSF) increased resistance of CY-treated mice, together with the marked restoration of APC and TNF-alpha productions. The capacity to produce interleukin 1-beta and TNF-alpha of peritoneal macrophages and also that to produce IL-6 of spleen cells were significantly enhanced by the in vivo administration of rhG-CSF in CY-treated mice. These results indicate that G-CSF may increase the functions of monocytes/macrophages directly or indirectly in vivo. Therefore, the therapeutic effect of rhG-CSF seems to consist of not only increases in the number and functions of neutrophils but also enhancement of monocyte/macrophage functions.
authors.affiliation: Dept. of Internal Medicine II, Nara Medical University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Sawaki
authors.forename: E
authors.initials: E
authors.lastname: Kita
authors.forename: K
authors.initials: K
authors.lastname: Mikasa
authors.forename: M
authors.initials: M
authors.lastname: Konishi
authors.forename: M
authors.initials: M
authors.lastname: Kumimatsu
authors.forename: S
authors.initials: S
authors.lastname: Kashiba
authors.forename: N
authors.initials: N
authors.lastname: Narita
mesh_terms: D000210:Acute-Phase Reaction / Q000276:immunology / Q000628:therapy*; D000818:Animals; D001202:Ascitic Fluid / Q000378:metabolism; D003520:Cyclophosphamide / Q000494:pharmacology*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D007273:Injections, Intramuscular; D007958:Leukocyte Count / Q000187:drug effects; D051379:Mice; D008809:Mice, Inbred C3H; D008813:Mice, Inbred ICR; D011552:Pseudomonas Infections / Q000276:immunology / Q000628:therapy*; D016188:Receptors, Granulocyte Colony-Stimulating Factor; D011994:Recombinant Proteins / Q000494:pharmacology; D000683:Serum Amyloid P-Component / Q000096:biosynthesis / Q000187:drug effects; D013154:Spleen / Q000378:metabolism
chemical_list: D016188:Receptors, Granulocyte Colony-Stimulating Factor; D011994:Recombinant Proteins; D000683:Serum Amyloid P-Component; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide